logo ecco
Portal

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Digital oral presentations: DOP Session 3 - Improving care of IBD (2020)

DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study

M. Høivik1, M. Lördal2, J. Burisch3, E. Langholz4, T. Knudsen5, M. Voutilainen6, B. Moum1, K. Anisdahl1, B. Saebo7, P. Haiko8, C. Malmgren9, M. Coskun10, H.O. Melberg11

1Department of Gastroenterology, Oslo University Hospital, Oslo, Norway, 2Department of Gastroenterology and Hepatology, Danderyds Hospital, Stockholm, Sweden, 3Department of Gastrounit- Medical Division, Hvidovre University Hospital, Hvidovre, Denmark, 4Department of Medical Gastroenterology, Herlev Hospital, Herlev, Denmark, 5Department of Medicine, Hospital South West Denmark, Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, 6Department of Gastroenterology, University of Turku, Turku, Finland, 7Takeda AS, Medical Affairs, Asker, Norway, 8Takeda Oy, Medical Affairs, Helsinki, Finland, 9Department of Medical Affairs, Takeda Pharma AB, Stockholm, Sweden, 10Department of Medical Affairs, Taastrup, Denmark, 11Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway

Background

Real-world data on time from diagnosis to first biologic treatment is limited for ulcerative colitis (UC) and Crohn’s disease (CD) patient populations.

Methods

This retrospective observational study collected data from the National Patient Registries and National Prescription Registries in Sweden (data on biologic use was only available for Stockholm [STK], Norway [NOR], Denmark [DEN]) and one university hospital database (Turku, Finland [FIN]) during 2010–2017 to investigate time from diagnosis to first biologic treatment for UC and CD. Patients with ≥2 ICD-10 diagnosis codes for UC (K51) or CD (K50) from 2010 or later were included; patients were classified according to their last code. The look-back period for SWE was until 2000, for NOR until 2008, for DEN until 1995, and for FIN until 2004. Time to first biologic was defined as the period from the first UC or CD code to first biologic record. In FIN, it was only possible to investigate infliximab (IFX).

Results

A total of 47,568 patients were included (STK n = 5594, NOR n = 20,761, FIN n = 2118, DEN n = 19,095). Of them, 30 397 patients had UC and 17 171 CD diagnosed during 2010–2017. Time to first biologic following diagnosis of UC or CD was decreased over time. For patients diagnosed with CD in 2015, in STK, NOR, FIN, and DEN, 30%, 35%, 25%, and 26%, respectively, received a biologic within 2 years; in 2010, the proportions were less than 10%, 20%, 5%, and 22%, respectively. FIN results may be attributed to only IFX use captured in the data sources. NOR had in most cohorts the shortest time between diagnosis and first treatment with a biologic agent, e.g. 33%, 35%, 36%, 34% and 33% of patients diagnosed with CD in 2011, 2012, 2013, 2014 and 2015, respectively, received a biologic already one month after diagnosis compared with 2%, 1%, 3%, 4% and 6%, respectively, in STK, 7%, 5%, 9%, 4% and 5%, respectively, in FIN and 3%, 10%, 28%, 12% and 23%, respectively, in DEN. Fewer UC than CD patients received biologics, but the time to first biologic was shortened to the same extent (Figure 1 and 2, respectively). In NOR, FIN and DEN, the most common biologic used was IFX for UC and CD, e.g. 18%, 14% and 15%, respectively, of UC and 35%, 17% and 35%, respectively, of CD patients diagnosed in 2015 had received IFX; in STK it was IFX for UC (8% of patients diagnosed in 2015) and adalimumab for CD (20% of patients diagnosed in 2015).

Conclusion

This retrospective observational study of >45 000 patients with inflammatory bowel disease in four Nordic countries showed reduced time between diagnosis and first biologic from 2010 to 2017, with the shortest time between diagnosis and first biologic in Norway. IFX was most commonly used.